Progenics inks licensing pact with Johns Hopkins University for agent to image prostate cancer using PET scan

Progenics Pharmaceuticals, Inc., engaged in developing innovative medicines for oncology, has entered into an exclusive worldwide licensing agreement with Johns Hopkins University for [18F]DCFPyL (PyL), a clinical-stage prostate specific membrane antigen (PSMA)-targeted imaging agent for prostate cancer.

PyL was developed by a team led by Martin G. Pomper, M.D., Ph.D. at the Johns Hopkins University School of Medicine. An early stage clinical trial of PyL with PET imaging in men with prostate cancer demonstrated uptake of PyL in sites of putative metastatic disease and primary tumors not seen with currently approved imaging techniques, suggesting the potential for high sensitivity and specificity in detecting prostate cancer. Read more.

Tags: Marketplace PET Prostate Trials

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap